Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y. Yang



Author of

  • +

    P1.12 - Poster Session 1 - NSCLC Early Stage (ID 203)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.12-005 - Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer (ID 1235)

      09:30 - 09:30  |  Author(s): Y. Yang

      • Abstract

      Background
      Asian ethnicity is associated with distinct molecular etiology, treatment response, and survival among patients with non-small cell lung cancer (NSCLC). This study examines the survival impact of platinum-based adjuvant chemotherapy for Asian patients with stage I-IIIA NSCLC.

      Methods
      This study recruited patients ³ 18 years old with histologically proven stage IA-IIIA NSCLC registered in the Taiwan Cancer Registry Database between January 2004 and December 2007. Platinum-containing adjuvant chemotherapy should be started within 90 days of the primary surgery. Kaplan-Meier survival curves, log-rank tests, and the Cox proportional hazards regression model were used to assess the influence of various risk factors on survival time.

      Results
      This study included 2,231 patients with stage IA to IIIA NSCLC who underwent primary surgery with a clear surgical margin. The percentages of all causes of death were significantly lower for the chemotherapy group in stage II and stage IIIA patients. Multivariate analysis identified platinum-based adjuvant chemotherapy as an independent prognostic factor for the overall survival of stage II (HR 0.61, 95% CI 0.39-0.94, p = 0.024) and IIIA (HR 0.71, 95% CI 0.52-0.96, p = 0.029) patients. Among these patients, those who received adjuvant chemotherapy demonstrated superior overall survival in both genders and in the subgroups of patients aged ³ 70 years and those with adenocarcinoma.

      Conclusion
      Platinum-based adjuvant chemotherapy should be considered in the treatment plan for Asian patients with resected stage II and stage IIIA NSCLC.